{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:01:46Z","timestamp":1786118506656,"version":"build-2736575974"},"reference-count":23,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Care"],"abstract":"<jats:p>Introduction: The aim of the study was to report the safety, efficacy, and patient-reported outcomes of a prospective trial of weekly hypofractionated radiotherapy (RT) for symptomatic locoregionally advanced breast cancer. Methods: In this single-arm, prospective phase II trial, 24 patients received a palliative RT course of 40 Gy delivered in five, weekly 8-Gy fractions. The primary endpoint was dose-limiting toxicity (DLT), defined as grade \u22653 acute radiation dermatitis. Secondary endpoints included objective response rate (ORR) and health-related quality of life (HRQoL), assessed longitudinally using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30\/BR23 and Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires. Results: All 24 enrolled patients completed the prescribed treatment. The regimen led to profound and statistically significant improvements in EORTC Global Health\/QoL scores (+44.1 points; 95% Confidence Intetval [CI]: 34.6 to 53.7; p &lt; 0.001) and pain scores (\u221233.3; 95% CI: \u221239.0 to \u221227.7; p &lt; 0.001) at 3 months, which were sustained at 6 months. At 3 months, the Overall Response Rate (ORR) was 40.9% (95% CI: 20.7% to 63.6%). The primary DLT was grade \u22653 acute dermatitis, occurring in 29.2% of patients; however, this toxicity was transient, with all events occurring at treatment completion and the rate decreasing to 8.3% by the 1-month follow-up. Conclusion: This signal-seeking study demonstrates the feasibility of a 40 Gy in 5-fraction palliative regimen. It presents a manageable, transient acute toxicity profile and offers promising signals of symptom palliation, locoregional disease control, and associated improvements in patient-reported QoL.<\/jats:p>","DOI":"10.1159\/000552778","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:01:05Z","timestamp":1782230465000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Ultra-Hypofractionated Palliative Radiotherapy for Symptomatic Locoregionally Advanced Breast Cancer: A Prospective, Single-Arm Phase II Trial of Toxicity and Quality-of-Life Outcomes"],"prefix":"10.1159","author":[{"given":"Haresh Kunhi","family":"Parambath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-6580","authenticated-orcid":false,"given":"Arun","family":"Thimmarayappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra Izzuddeen","family":"KN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali V.","family":"Ramdulari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.11.065"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000360054"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231164537"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.1143"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.02.008"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.974"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.94.3.361"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13566-016-0278-z"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84872-9"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.06.006"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1702907"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1320-2"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy054"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.21037\/apm.2018.05.13"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11024"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-126"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-023-02357-7"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.51253\/pafmj.v73i4.7443"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30932-6"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/apm-23-147"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31930"}],"container-title":["Breast Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:00:48Z","timestamp":1786032048000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1159\/000552778","archive":["Portico"],"relation":{},"ISSN":["1661-3791","1661-3805"],"issn-type":[{"value":"1661-3791","type":"print"},{"value":"1661-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}